 Home > Active Ingredient News > Endocrine System > J INTERN MED: Patients with hip fractures are at increased risk of fracture after stopping anti-osteoporosis drugs

J INTERN MED: Patients with hip fractures are at increased risk of fracture after stopping anti-osteoporosis drugs

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

virtual journal

biomarkers journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, an authoritative journal in the field of internal medicine published a research article in the Journal of Internal Medicine.

Osteoporosis

The researchers conducted a comparative study of the effectiveness of a cohort study design based on a national population

According to the patient's subsequent medication mode, patients are divided into continuous or non-continuous denosumab or bisphosphonate users

Compared with those who continued to use denosumab, non-sustained denosumab users had severe osteoporotic fractures (hazard ratio (HR)=1.

It can be seen that discontinuation of denosumab will lead to an increased risk of osteoporotic fractures, especially vertebral fractures, and the increased risk often manifests within one year after stopping the drug

Discontinuation of denosumab will lead to an increased risk of osteoporotic fractures, especially vertebral fractures, and the increased risk often manifests within one year after stopping the drug

Original source:

Shau-Huai Fu.

Increased fracture risk after discontinuation of anti- osteoporosis medications among hip fracture patients: a population-based cohort study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Hydroxyprogesterone

CAS No.: 68-96-2

$1/KG EXW

Medroxyprogesterone Acetate

CAS No.: 71-58-9

$1/KG EXW

Prostaglandin E1 Impurity 2

CAS No.: 745-65-3

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.